Featureform Competitors

Symbiance was founded in 90's and established as a technology enabled Global CRO. We are experts in delivering innovative AI enabled products, data solutions, medical writing, drug safety, and Regulatory management for pharmaceutical/bio-tech companies. At Symbiance, we are a trusted partner to our clients, helping to bring medical breakthroughs to market quickly, accurately and cost effectively. With a combined 100 years of experience, dedication to personalized communication, and a relationship for success, Symbiance delivers numbers that matter. Symbiance is a renowned niche provider of Clinical data management, Clinical data standards, Biostatistics Statistical Programming Medical writing Pharmacovigilance Regulatory Operations Symbiance’s values Provide clients with faster solutions using advanced technologies with un-compromised quality. Establish and maintain open/transparent partnership with our clients. Symbiance is about, "creating relationships for success".

Phesi has the industry’s most comprehensive and dynamic clinical trials database and predictive analytics tools to help trial sponsors make quick and informed decisions to expedite drug development. Our distinguished team works side-by-side with its clients to analyze data, answer questions, and offer informed solutions to benefit study sponsors, investigators, and ultimately patients. Phesi has been applying its innovative technology and deep expertise to help life sciences companies for over 10 years. Our experts work with study sponsors to drive solutions from clinical development planning through trial implementation to optimize protocol designs, select the best investigator sites, shorten enrollment cycle times, select and manage CROs, and much more.

Collaborations Pharmaceuticals, Inc. works on drug discovery for rare and neglected diseases. We develop and license our AI software as well as provide fee for services for pharmaceutical and consumer product services. To date we have won with collaborators $23.5M in grants since 2016.